Blueprint Medicines Corp. has identified cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.

A Suzhou Puhe Biopharma Co. Ltd. patent reports new Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors described as potentially useful for the treatment of cancer.

Cyclin-dependent kinase 12 (CDK12)/cyclin K and CDK13/cyclin K inhibitors have been described in a Nanjing Sanhome Pharmaceutical Co. Ltd. patent and are reported to be potentially useful for the treatment of cancer.

Insilico Medicine Inc. has prepared and tested new spirocyclic mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer and viral infections.

Camptothecin derivatives reported to be useful for the treatment of cancer have been disclosed in a recent Genescience Pharmaceuticals Co. Ltd. patent.

Patents from Apichope Pharmaceutical Co. Ltd. describe bicyclic compounds characterized as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors.

Hainan Simcere Pharmaceutical Co. Ltd. has prepared bicyclic compounds acting as fibroblast growth factor receptor 3 (FGFR3) inhibitors potentially useful for the treatment of cancer.

Insilico Medicine Inc. has identified compounds acting as tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer and metabolic disease.

Oncozen Co. Ltd. has patented new proteolysis targeting chimera (PROTAC) compounds comprising a heat shock protein 90 (HSP90) binding moiety covalently bound to hepatocyte growth factor receptor (HGFR; MET) targeting moiety through a linker.

JS Innomed Holdings Ltd. has identified Heterocyclic compounds characterized as serine/threonine-protein kinase ULK1 and/or ULK2 inhibitors.